Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

Aim: To investigate whether resveratrol (RSV) can improve non-alcoholic fatty liver disease (NAFLD) and to find the possible mechanism. Methods: Rats fed a high-fat diet were treated with RSV. The liver histology was observed. Hyperinsulinemic euglycemic clamp was performed to assess insulin sensiti...

Full description

Saved in:
Bibliographic Details
Published inActa pharmacologica Sinica Vol. 29; no. 6; pp. 698 - 706
Main Authors Shang, Jing, Chen, Lu-lu, Xiao, Fang-xi, Sun, Hui, Ding, Hong-cheng, Xiao, Hu
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.06.2008
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aim: To investigate whether resveratrol (RSV) can improve non-alcoholic fatty liver disease (NAFLD) and to find the possible mechanism. Methods: Rats fed a high-fat diet were treated with RSV. The liver histology was observed. Hyperinsulinemic euglycemic clamp was performed to assess insulin sensitivity. Fat accumulation was induced in HepG2 cells, and the cells were treated with RSV. AMP-activated protein kinase (AMPK) phosphorylation levels were determined both in the animal study and cell study. Results: Rats fed a high-fat diet developed abdominal obesity, NAFLD, and insulin resistance (IR), which were markedly improved by 10 weeks of RSV administration. RSV treatment prevented triacylglycerol (TG) accumulation in HepG2 ceils that were incubated with high concentration of glucose and insulin. Both in vivo and in vitro studies showed that RSV treatment could promote the phosphorylation of AMPK, which in this study, suppressed 2 lipogenesis gene expressions, contributing to the improvement of NAFLD and IR. Conclusion: The results indicated that by reducing TG accumulation and improving IR, RSV could protect the liver from NAFLD. The activation of AMPK was involved in the mechanism. RSV has the therapeutic potential for preventing or treating NAFLD and IR-related metabolic disorders.
Bibliography:R575
non-alcoholic fattyliver disease
resveratrol; insulin resistance; AMP-activated protein kinase; non-alcoholic fattyliver disease
AMP-activated protein kinase
resveratrol
insulin resistance
R96
31-1347/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1671-4083
1745-7254
DOI:10.1111/j.1745-7254.2008.00807.x